

COMMITTEE SUBSTITUTE

FOR

COMMITTEE SUBSTITUTE

FOR

## **Senate Bill No. 7**

(By Senators Stollings, Jenkins, Miller,  
Plymale, Foster, Klempa and Kirkendoll)

---

[Originating in the Committee on the Judiciary;  
reported January 20, 2012.]

---

A BILL to amend the Code of West Virginia, 1931, as amended, by adding thereto a new section, designated §16-4C-24, relating generally to allowing State Police, police, sheriffs and fire and emergency service personnel to possess Naloxone or other approved opioid antagonist to administer in opioid drug overdoses; defining terms; providing for training; establishing training requirements for first responders who may administer

opioid antagonists; establishing criteria under which a first responder may administer an opioid antagonist; granting immunity to health care providers who prescribe, dispense or distribute Naloxone or other approved opioid antagonist related to a training program; granting immunity to initial responders who administer or fail to administer an opioid antagonist; providing for data gathering and reporting; and authorizing emergency rulemaking.

*Be it enacted by the Legislature of West Virginia:*

That the Code of West Virginia, 1931, as amended, be amended by adding thereto a new section, designated §16-4C-24, to read as follows:

**ARTICLE 4C. EMERGENCY MEDICAL SERVICES ACT.**

**§16-4C-24. Administration of an opioid antidote in an emergency situation.**

- 1 (a) For purposes of this section:
- 2 (1) “Initial responder” means any emergency medical
- 3 service personnel covered under this article and any member
- 4 of the State Police, any sheriff, any deputy sheriff, any
- 5 municipal police officer, any volunteer and paid firefighters
- 6 and any other similar persons who respond to emergencies.

7       (2) “Licensed health care provider” means a person,  
8 partnership, corporation, professional limited liability  
9 company, health care facility or institution licensed by or  
10 certified in this state to provide health care or professional  
11 health care services, including but not limited to a physician,  
12 osteopathic physician, hospital or emergency medical service  
13 agency.

14       (3) “Opioid antagonist” means naloxone hydrochloride  
15 or other substance that is approved by the federal Food and  
16 Drug Administration for the treatment of a drug overdose by  
17 intranasal administration.

18       (4) “Opioid overdose prevention and treatment training  
19 program” or “program” means any program operated or  
20 approved by the Office of Emergency Medical Services to  
21 train individuals to prevent, recognize and respond to an  
22 opiate overdose, and that provides, at a minimum, training  
23 in all of the following:

24       (A) The causes of an opiate overdose;

25       (B) How to recognize the symptoms of an opioid over-  
26 dose;

27 (C) How to contact appropriate emergency medical  
28 services; and

29 (D) How to administer an opioid antagonist.

30 (b) A licensed health care provider who is permitted by  
31 law to prescribe an opioid antagonist may, if acting with  
32 reasonable care, prescribe and subsequently dispense or  
33 distribute an opioid antagonist in conjunction with an opioid  
34 overdose prevention and treatment training program,  
35 without being subject to civil liability or criminal prosecu-  
36 tion, unless the act was the result of the licensed health care  
37 provider's gross negligence or willful misconduct. This  
38 immunity shall apply to the licensed health care provider  
39 even when the opioid antagonist is administered by and to  
40 someone other than the person to whom it is prescribed.

41 (c) An initial responder who is not otherwise licensed to  
42 administer an opioid antagonist may administer an opioid  
43 antagonist in an emergency situation if:

44 (1) The administration is performed without a fee;

45 (2) The initial responder has successfully completed the  
46 training required by subdivision (4), subsection (a) of this  
47 section; and

48       (3) The administration of the opioid antagonist is done  
49 after consultation with medical command personnel: *Pro-*  
50 *vided*, That an initial responder otherwise meets the qualifi-  
51 cations of this subsection may administer an opioid antago-  
52 nist without consulting with medical command if her or she  
53 is unable to so consult due to an inability to contact medical  
54 command because of circumstances outside the control of the  
55 initial responder or if there is insufficient time for such  
56 consultation based upon the emergency conditions presented.

57       (d) An initial responder who meets the requirements of  
58 subsection (c) of this section, acting in good faith, is not, as  
59 a result of his or her actions or omissions, liable for any  
60 violation of any professional licensing statute, subject to any  
61 criminal prosecution arising from or relating to the unautho-  
62 rized practice of medicine or the possession of an opioid  
63 antagonist, or subject to any civil liability with respect to the  
64 administration of or failure to administer the opioid antago-  
65 nist unless the act or failure to act was the result of the  
66 initial responder's gross negligence or willful misconduct.

67       (e) Data regarding each opioid overdose prevention and  
68 treatment program that the Office of Emergency Medical  
69 Services operates or recognizes as an approved program shall

70 be collected and reported by January 1, 2016, to the Legisla-  
71 tive Oversight Commission on Health and Human Resources  
72 Accountability. The data collected and reported shall  
73 include:

74 (1) Number of training programs operating in an OEMS  
75 designated training center;

76 (2) Number of individuals who have received a prescrip-  
77 tion for, and training to administer, an opioid antagonist;

78 (3) Number of opioid antagonist doses prescribed;

79 (4) Number of opioid antagonist doses administered;

80 (5) Number of individuals who received the opioid  
81 antagonist who were properly revived;

82 (6) Number of individuals who received the opioid  
83 antagonist who were not revived; and

84 (7) Number of adverse events associated with an opioid  
85 overdose prevention and treatment program, including a  
86 description of the adverse events.

87 (f) To implement the provisions of this section, including  
88 establishing the standards for certification and approval of  
89 opioid overdose prevention and treatment training programs,  
90 the Office of Emergency Medical Services may promulgate  
91 emergency rules pursuant to the provisions of section fifteen,  
92 article three, chapter twenty-nine-a of this code.

